Has Actemra Been Authorized for COVID-19 Pneumonia?
Yes, Actemra (tocilizumab) received Emergency Use Authorization (EUA) from the FDA in June 2021 for hospitalized adults with COVID-19 pneumonia requiring supplemental oxygen or mechanical ventilation. It targets cytokine release syndrome by blocking interleukin-6 receptors, reducing inflammation in severe cases.[1][2]
What Do Clinical Trials Show?
The RECOVERY trial (UK) found tocilizumab reduced 28-day mortality by 4% in hospitalized COVID-19 patients on oxygen or ventilation (31% vs 35% placebo). The REMAP-CAP trial reported 29% lower risk of death or organ support. FDA cited these phase 3 results for EUA, though full approval for COVID-19 remains pending.[1][3]
How Is It Administered for COVID-19?
Given as a single IV infusion (8 mg/kg, max 800 mg) alongside steroids like dexamethasone. Used only in hospital settings for patients with confirmed COVID-19 pneumonia and elevated inflammatory markers (e.g., CRP >75 mg/L). Not for mild cases or outpatients.[2][4]
What Are the Key Risks and Side Effects?
Common issues include infections (higher risk with immunosuppression), liver enzyme elevation, and infusion reactions. FDA warns of fatal infections like tuberculosis; monitor closely. Not recommended if active untreated infections or neutropenia.[1][2]
Is It Still Recommended Today?
Post-Omicron, NIH guidelines list tocilizumab as an option for severe COVID-19 (oxygen saturation <94%) despite antivirals or monoclonal antibodies. Use declined with vaccines and milder variants, but remains relevant for high-risk hospitalized pneumonia cases.[4][5]
Alternatives to Actemra for COVID Pneumonia
| Drug | Mechanism | Key Use Case | Mortality Benefit (Trials) |
|------|-----------|--------------|----------------------------|
| Baricitinib (Olumiant) | JAK inhibitor | Hospitalized, severe COVID | 20-30% reduction[6] |
| Dexamethasone | Corticosteroid | Oxygen-dependent | 20% reduction (RECOVERY)[3] |
| Sotrovimab (if available) | Monoclonal antibody | Early, high-risk | Prevents hospitalization[7] |
Availability and Cost Considerations
Actemra is FDA-approved for rheumatoid arthritis; COVID EUA expanded access. Average U.S. hospital dose costs $2,000-$3,000, often covered by insurers for authorized uses. Genentech (Roche) manufactures; no generic yet.[8]
Sources
[1]: FDA EUA Fact Sheet
[2]: FDA Authorization Announcement
[3]: RECOVERY Trial (NEJM)
[4]: NIH COVID Treatment Guidelines
[5]: IDSA Guidelines
[6]: ACTT-2 Trial (NEJM)
[7]: COMET-ICE Trial
[8]: DrugPatentWatch - Actemra